查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1383663

口服蛋白质和胜肽市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、按应用、地区、竞争预测和机会细分，2018-2028F

Oral Proteins & Peptides Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Application, By Region, By Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球口服蛋白质和胜肽市场价值为 13.3 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2028 年CAGR为12.10%。全球口服蛋白质和胜肽市场是製药和製药产业中快速成长的细分市场。生物技术产业。口服蛋白质和胜肽是可以口服给药的生物活性分子，通常以片剂、胶囊或液体的形式作为注射剂的替代品。这种给药模式具有多种优点，包括提高病患依从性、减少疼痛和降低医疗成本。

主要市场驱动因素

慢性病盛行率上升

市场概况
预测期 2024-2028
2022 年市场规模 13.3亿美元
2028 年市场规模 26.4亿美元
2023-2028 年CAGR 12.10%
成长最快的细分市场 普卡那肽
最大的市场 北美洲

慢性病的流行推动口服蛋白质和胜肽市场成长的最明显方式是需要治疗的患者数量的急剧增加。随着全球人口老化和生活方式变得越来越久坐和不健康，慢性病变得越来越普遍。这意味着更多的潜在患者可能会受益于口服蛋白质和胜肽疗法。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球口服蛋白质与胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 依药物类型
    • 按应用
    • 按地区

第 6 章：北美口服蛋白质与胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲口服蛋白质与胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区口服蛋白质与胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲口服蛋白质与胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲口服蛋白质和胜肽市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（降钙素、胰岛素、利那洛肽、奥曲肽、普莱卡那肽）
    • 按应用（骨骼疾病、糖尿病、胃病和消化系统疾病、荷尔蒙失调）
    • 按国家/地区
  • MEA：国家分析
    • 南非口服蛋白质和胜肽
    • 沙乌地阿拉伯口服蛋白质和胜肽
    • 阿联酋口服蛋白质和胜肽
    • 科威特口服蛋白质和胜肽

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • AbbVie Inc.
    • Merck & Co Inc
    • Pfizer Inc
    • Novo Nordisk A/S
    • Hoffmann-La Roche Inc
    • Sanofi SA
    • AstraZeneca PLC
    • Bristol-Myers Squibb Co
    • Tarsa Therapeutics Inc
    • Novartis AG

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 18807

Global Oral Proteins & Peptides Market has valued at USD 1.33 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 12.10% through 2028. The global oral proteins and peptides market is a rapidly growing segment within the pharmaceutical and biotechnology industry. Oral proteins and peptides are bioactive molecules that can be administered orally, typically in the form of tablets, capsules, or liquids, as an alternative to injections. This mode of administration offers several advantages, including improved patient compliance, reduced pain, and lower healthcare costs.

Key Market Drivers

Rising Prevalence of Chronic Diseases

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.33 Billion
Market Size 2028USD 2.64 Billion
CAGR 2023-202812.10%
Fastest Growing SegmentPlecanatide
Largest MarketNorth America

The most obvious way in which the prevalence of chronic diseases is fueling the growth of the oral proteins and peptides market is through the sheer increase in the number of patients requiring treatment. As the global population ages and lifestyles become increasingly sedentary and unhealthy, chronic diseases are becoming more common. This translates to a larger pool of potential patients who may benefit from oral protein and peptide therapies.

Patients are increasingly seeking treatment options that are not only effective but also convenient. Many individuals with chronic conditions require long-term or even lifelong therapy, which can be burdensome with traditional treatment methods such as injections or infusions. Oral proteins and peptides offer a more patient-friendly approach, as they can be administered simply by swallowing a pill or liquid, eliminating the need for painful and frequent injections.

Non-adherence to prescribed treatments is a significant issue in managing chronic diseases. Oral formulations provide a solution to this problem by increasing patient compliance. When treatment is easier to administer and less intrusive, patients are more likely to stick to their prescribed regimens, leading to better health outcomes.

The burden of chronic diseases on healthcare systems is substantial. Hospitalizations, doctor visits, and frequent injections can drive up healthcare costs significantly. Oral proteins and peptides can help mitigate some of these costs by reducing the need for invasive medical procedures and hospital stays. This makes them an attractive option for both patients and healthcare providers.

Scientific advancements in oral drug delivery technologies have enhanced the bioavailability and stability of proteins and peptides in the gastrointestinal tract. Enteric coatings, nanoparticles, and other formulations have improved the efficiency of oral drug absorption. This has expanded the range of diseases that can be effectively treated with oral therapies, further driving market growth.

Researchers and pharmaceutical companies are actively developing oral protein and peptide therapies tailored to specific chronic diseases. For example, oral insulin for diabetes management and oral biologics for inflammatory bowel disease are in various stages of development. This targeted approach can significantly improve treatment outcomes and is likely to drive market expansion.¬

Technological Advancements in Drug Delivery

Historically, one of the major challenges in administering proteins and peptides orally was their vulnerability to degradation in the harsh environment of the gastrointestinal tract. However, technological breakthroughs have paved the way for the development of enteric coatings and specialized formulations that protect these fragile molecules. This has significantly improved their bioavailability and stability, making oral delivery a viable option for an increasing number of therapeutic proteins and peptides.

Nanotechnology has ushered in a new era in drug delivery. Nanoparticles and nanocarriers can be designed to encapsulate and protect proteins and peptides until they reach their target sites in the body. This precise delivery system not only enhances therapeutic efficacy but also minimizes side effects. Such innovations are driving the development of oral protein and peptide therapies for a wide range of diseases.

Researchers have developed absorption enhancers that can facilitate the uptake of proteins and peptides in the gastrointestinal tract. These substances improve the transport of therapeutic molecules across the intestinal epithelium, enhancing their bioavailability. As a result, oral protein and peptide therapies can achieve therapeutic levels in the bloodstream, making them more effective.

Technology has enabled the creation of customized drug delivery systems tailored to the needs of specific proteins and peptides. These systems can be fine-tuned to release the drug at the right time and in the right place within the body. Such precision ensures optimal therapeutic outcomes and minimizes the risk of adverse effects.

Technological advancements have also extended to the design of patient-centric devices that aid in the administration of oral proteins and peptides. These devices ensure accurate dosing and ease of use, improving patient compliance. For example, smart pill bottles can remind patients to take their medication and provide valuable data to healthcare providers.

Progress in drug delivery technology is expanding the therapeutic landscape for oral proteins and peptides. Previously, these molecules were primarily used for conditions like diabetes and gastrointestinal disorders. However, with improved delivery methods, researchers are exploring their use in a broader range of diseases, including cancer, autoimmune disorders, and rare genetic conditions.

Diabetes Management Revolution

Traditionally, diabetes management primarily relied on insulin injections, often multiple times a day. This regimen posed a significant burden on patients, impacting their quality of life and adherence to treatment. The introduction of oral proteins and peptides for diabetes management represents a paradigm shift, offering a less invasive and more convenient alternative.

Oral insulin is at the forefront of the diabetes management revolution. Researchers and pharmaceutical companies are actively working on developing formulations that allow insulin to be administered orally, eliminating the need for injections. Such innovations can drastically improve patient compliance, particularly among those who are reluctant to self-inject.

Technological advancements in drug delivery, including the use of absorption enhancers and nanoparticle formulations, have greatly enhanced the bioavailability of oral insulin and other diabetes-related proteins and peptides. This means that these molecules can survive the digestive process and reach the bloodstream in therapeutic concentrations, ensuring effective glycemic control.

The revolution in diabetes management is marked by a patient-centric approach. Oral proteins and peptides provide patients with more autonomy and control over their treatment. This empowerment can lead to better self-management of diabetes and improved long-term outcomes.

Hypoglycemia, or low blood sugar, is a common and potentially dangerous side effect of insulin therapy. Oral insulin formulations offer the advantage of mimicking the body's natural insulin release more closely, reducing the risk of hypoglycemia compared to rapid-acting injectable insulin.

The availability of oral proteins and peptides for diabetes management is broadening the spectrum of treatment options. This is especially crucial for individuals with specific needs, such as children with type 1 diabetes, who may benefit from less invasive and more user-friendly therapies.

Targeted Treatment for Gastrointestinal Disorders

Gastrointestinal disorders encompass a wide range of conditions, including inflammatory bowel disease (IBD), celiac disease, Crohn's disease, and irritable bowel syndrome (IBS). These disorders often require localized treatment within the gastrointestinal tract. Oral proteins and peptides can be engineered and administered to precisely target affected areas, delivering therapeutic molecules directly to the source of the disease.

Traditional treatments for gastrointestinal disorders, such as corticosteroids and immunosuppressants, can lead to systemic side effects due to their widespread distribution in the body. Targeted oral therapies, on the other hand, minimize these systemic side effects by concentrating the treatment where it's needed, thereby enhancing patient comfort and adherence.

By specifically targeting the gastrointestinal tract, oral proteins and peptides can achieve higher concentrations at the site of inflammation or damage. This localized treatment approach enhances therapeutic efficacy, allowing for more effective management of conditions like IBD and celiac disease.

Many gastrointestinal disorders require regular endoscopies, colonoscopies, or other invasive procedures to assess disease progression and administer treatments. Targeted oral therapies can potentially reduce the need for these invasive interventions, making treatment more convenient and less burdensome for patients.

Technological innovations in drug delivery, such as enteric coatings and nanoparticles, have improved the bioavailability and stability of oral proteins and peptides within the gastrointestinal environment. These advancements ensure that the therapeutic molecules reach their intended target effectively.

As research and development in this field continue to progress, targeted oral therapies are being explored for an expanding array of gastrointestinal disorders. This includes conditions that were previously difficult to treat effectively, offering new hope to patients and increasing the market's growth potential.

Key Market Challenges

Stability and Bioavailability

The oral administration of proteins and peptides presents a significant challenge due to their susceptibility to degradation in the harsh environment of the gastrointestinal tract. Maintaining stability and ensuring sufficient bioavailability of these molecules is a complex problem that requires sophisticated formulation techniques.

Dosage and Dosing Frequency

Determining the appropriate dosage and dosing frequency for oral protein and peptide therapies is not straightforward. Finding the right balance between effective treatment and minimizing side effects is a delicate process that often requires extensive clinical testing.

Manufacturing Complexity

The production of oral proteins and peptides can be complex and costly. Maintaining the stability and purity of these molecules during manufacturing is a challenge that must be addressed to ensure consistent product quality.

Key Market Trends

Nanotechnology and Drug Delivery Innovations

Nanotechnology is revolutionizing drug delivery in the oral proteins and peptides market. Nanoparticles and nanocarriers are being designed to encapsulate and protect these delicate molecules, enabling precise delivery and enhanced bioavailability. These innovations will expand the range of treatable diseases and improve therapeutic outcomes.

Oral Insulin Advancements

Oral insulin is a hot topic in diabetes management. Ongoing research aims to overcome the challenges of delivering insulin orally, potentially transforming the way diabetes is treated. Innovations in oral insulin formulations have the potential to revolutionize diabetes care by eliminating the need for injections.

Microbiome-Based Therapies

The gut microbiome plays a critical role in overall health, including the efficacy of oral protein and peptide therapies. Researchers are exploring microbiome-based therapies that can enhance drug absorption and response. This trend holds promise for improving treatment outcomes in gastrointestinal disorders.

Segmental Insights

Drug Type Insights

The anticipated surge in the forecast for Plecanatide drug type within the Global Oral Proteins & Peptides Market can be attributed to several key factors. Firstly, Plecanatide has exhibited remarkable efficacy in the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), addressing a substantial unmet medical need. Moreover, its oral administration route offers a convenient alternative to traditional injectable protein therapies, enhancing patient compliance. Additionally, ongoing research and development efforts, including potential label expansions for Plecanatide, are poised to further bolster its market penetration. As healthcare providers and patients increasingly recognize the therapeutic benefits of this drug, coupled with growing awareness of gastrointestinal disorders, Plecanatide is expected to witness a significant rise in demand, propelling its prominence in the global oral proteins and peptides sector.

Application Insights

The projected increase in forecast for Gastric & Digestive Disorders within the Global Oral Proteins & Peptides Market stems from several compelling factors. Firstly, there is a growing prevalence of gastric and digestive disorders globally, driven by dietary changes, lifestyle factors, and an aging population. As these conditions become more prevalent, the demand for effective treatments, such as oral proteins and peptides, is expected to surge. Additionally, advancements in pharmaceutical research and development have led to the creation of innovative therapies targeting these disorders, offering promising treatment options for patients. The convenience and patient-friendly nature of oral administration further contribute to the expected rise in demand for oral proteins and peptides in this therapeutic area. Consequently, as awareness and acceptance of these novel therapies grow, Gastric & Digestive Disorders are anticipated to witness an upward trajectory in the global market, meeting the evolving healthcare needs of patients worldwide.

Regional Insights

The North American region is poised for a significant upturn in the forecast of the Global Oral Proteins & Peptides Market in 2022 for several compelling reasons. First and foremost, North America boasts a robust healthcare infrastructure and a well-established pharmaceutical industry, fostering an environment conducive to the development and commercialization of oral protein and peptide-based therapies. Additionally, a heightened focus on research and innovation, coupled with substantial investments in biotechnology and pharmaceutical companies, has led to the emergence of cutting-edge oral protein and peptide drug candidates specifically tailored to address various medical conditions. Furthermore, a growing patient population, along with increasing awareness and acceptance of these innovative treatments, is expected to drive substantial demand in the region. As regulatory agencies continue to streamline approval processes and as healthcare providers increasingly integrate these therapies into their treatment protocols, North America is primed to experience a noteworthy surge in its share of the Global Oral Proteins & Peptides Market.

Key Market Players

AbbVie Inc.

Merck & Co Inc

Pfizer Inc

Novo Nordisk A/S

Hoffmann-La Roche Inc

Sanofi SA

AstraZeneca PLC

Bristol-Myers Squibb Co

Tarsa Therapeutics Inc

Novartis AG

Report Scope:

In this report, the Global Oral Proteins & Peptides Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Proteins & Peptides Market, By Drug Type:

  • Calcitonin
  • Insulin
  • Linaclotide
  • Octreotide
  • Plecanatide

Oral Proteins & Peptides Market, By Application:

  • Bone Diseases
  • Diabetes
  • Gastric & Digestive Disorders
  • Hormonal Disorders

Oral Proteins & Peptides Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Oral Proteins & Peptides Market.

Available Customizations:

  • Global Oral Proteins & Peptides market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Proteins & Peptides Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 5.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Application
    • 5.3.3. By Region

6. North America Oral Proteins & Peptides Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 6.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oral Proteins & Peptides Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Oral Proteins & Peptides Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Oral Proteins & Peptides Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application

7. Europe Oral Proteins & Peptides Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 7.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oral Proteins & Peptides Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
    • 7.3.2. United Kingdom Oral Proteins & Peptides Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
    • 7.3.3. France Oral Proteins & Peptides Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Oral Proteins & Peptides Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Oral Proteins & Peptides Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application

8. Asia-Pacific Oral Proteins & Peptides Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 8.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oral Proteins & Peptides Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Japan Oral Proteins & Peptides Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
    • 8.3.3. India Oral Proteins & Peptides Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Australia Oral Proteins & Peptides Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
    • 8.3.5. South Korea Oral Proteins & Peptides Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application

9. South America Oral Proteins & Peptides Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 9.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oral Proteins & Peptides Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Oral Proteins & Peptides Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Oral Proteins & Peptides Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Oral Proteins & Peptides Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
    • 10.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oral Proteins & Peptides Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Oral Proteins & Peptides Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Oral Proteins & Peptides Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
    • 10.3.4. Kuwait Oral Proteins & Peptides Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. AbbVie Inc.
    • 14.6.2. Merck & Co Inc
    • 14.6.3. Pfizer Inc
    • 14.6.4. Novo Nordisk A/S
    • 14.6.5. Hoffmann-La Roche Inc
    • 14.6.6. Sanofi SA
    • 14.6.7. AstraZeneca PLC
    • 14.6.8. Bristol-Myers Squibb Co
    • 14.6.9. Tarsa Therapeutics Inc
    • 14.6.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer